Highlights IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.17 ^USD	0.00%		-1.68%	-37.77%

05-15	HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating	MT
05-14	IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	04-09	CI
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	03-06	CI
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	12-21	CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	11-10	CI
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress	23-10-23	CI
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center	23-07-28	CI
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone	23-06-14	CI
IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
IO Biotech Teams Up With Merck to Evaluate IO102-IO103 Combined With Keytruda to Treat Resectable Tumors	22-11-03	MT
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma	22-05-18	CI
IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IO Biotech, Inc.

Equities

IOBT

US4497781090

Highlights

Filters